Hydroxamate based inhibitors of low affinity IgE receptor (CD23) processing

Bioorganic and Medicinal Chemistry Letters

Volumn 8, Issue 1, 1998, Pages 23-28

  Bailey, Stuart ^a   Bolognese, Brian ^b   Buckle, Derek R ^a   Faller, Andrew ^c   Jackson, Sally ^a   Louis Flamberg, Pearl ^b   McCord, Mark ^b   Mayer, Ruth J ^b   Marshall, Lisa A ^b   Smith, David G ^c  

^a GLAXOSMITHKLINE   (United Kingdom)

^b Upper Merion   (United States)

^c New Frontiers Science Park (North)   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BATIMASTAT; COLLAGENASE; HYDROXAMIC ACID; IMMUNOGLOBULIN E RECEPTOR; METALLOPROTEINASE INHIBITOR;

ARTICLE; CELL MEMBRANE; CONTROLLED STUDY; DIASTEREOISOMER; DRUG DESIGN; DRUG SYNTHESIS; NONHUMAN; PROTEIN DEGRADATION;

HUMANS; HYDROXAMIC ACIDS; PHENYLALANINE; PROTEASE INHIBITORS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTORS, IGE; STRUCTURE-ACTIVITY RELATIONSHIP; THIOPHENES;

EID: 17144441571     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(97)10148-2     Document Type: Article

References (20)

1. 1. Yukawa, K.; Kikutani, H.; Owaki, K.; Yamasaki, K.; Yokota, A.; Nakamura, H.; Barumian, E. L.; Hardy, R. R.; Suemura, M.; Kishimoto, T. J. Immunol. 1987, 138, 2576.
2. 2. See Conrad, D. H. Ann. Rev. Immunol 1990, 8, 623.
3. 3. Lettelier, M.; Sarfati, M.; Delespesse, G. Molec. Immunol. 1989, 26, 1105.
4. 4. Delespesse, G.; Sarfati, M.; Wu, C. Y.; Fournier, S.; Letellier, M. Immunol. Rev. 1992, 125, 77.
5. 5. Letellier, M.; Nakajima, T.; Pulido-Cejudo, G.; Hofstetter, H.; Delespesse, G. J. Exp. Med. 1990, 172, 693.
6. 6. Christie, G. unpublished results.
7. 7. Mayer, R. J. unpublished results.
8. 8. Rich, D. H. In Comprehensive Medicinal Chemistry, Ed. Sammes, P. G., Pergamon, Oxford, 1990, vol 2, p391.
9. 9. Beckett, R. P.; Davidson, A. H.; Drummond, A. H.; Huxley, P.; Whittaker, M. Drug Discovery Today, 1996, 1, 16.
10. 10. For nomenclature see: Schechter, I.; Berger, A. Biochem. Biophys. Res. Commun. 1967, 27, 157; 1968, 32, 898.
11. 10. For nomenclature see: Schechter, I.; Berger, A. Biochem. Biophys. Res. Commun. 1967, 27, 157; 1968, 32, 898.
12. 11. Johnson, W. S.; Daub, G. H. Org. Reactions, 1951, 6, 1.
13. 12. Beckett, R. P.; Crimmin, M. J.; Davis, M. H.; Spavold, Z. Synlett, 1993, 137.
14. 13. Simon, R. J.; Kania, R. S.; Zuckermann, R. N.; Huebner, V. D.; Jewell, D. A.; Bankville, S.; Wang, S.; Rosenberg, S.; Marlowe, C. K.; Spellmeyer, D. D.; Tan, R.; Frankel, A. D.; Santi, D. A.; Cohen, F. E.; Bartlett, P. A. Proc. Natl. Acad. Sci., 1992, 89, 9367.
15. 14. Nikam, S. S.; Kornberg, B. E.; Johnson, D. R.; Doherty, A. M. Tetrahedron Lett., 1995, 36, 197.
16. 15. Morphy, J. R.; Millican, T. A.; Porter, J. R. Current Medicinal Chemistry, 1995, 2, 743.
17. 16. Brown, P. D. Pharmaceutical News, 1995, 2, 29.
18. 50 values were determined from the line of best fit of the concentration-response curves.
19. 50 values were determined from the Line of best fit of the concentration-response curves.
20. 19. Johnson, W. H.; Roberts, N. A.; Borkakot, N. J. Enz. Inhib. 1987, 2, 1.